Proteomics

Dataset Information

0

Aberrant SUMOylation restricts the targetable cancer immunopeptidome


ABSTRACT: A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandomics and identified a function of activated SUMOylation in restricting the immunopeptidome landscape. Importantly, aberrant SUMOylation suppressed a unique HLA-I peptide and oncoprotein-derived neoepitope repertoire, enabling cancer cells to evade T cell immune surveillance. Mechanistically, SUMOylation impaired the immunoproteasome constitution and proteolytic activity, thus limiting the diversity of the peptide landscape. Further, SUMOylation altered TAP1 transporter binding preferences, thereby mimicking viral immune evasion strategies. As an actionable application, pharmacological inhibition of SUMOylation unmasked the targetable immunopeptidome and enhanced the tumor cell susceptibility to T cell killing. These findings highlight SUMOylation as a critical regulator of the adaptive anti-tumor immune response. We propose SUMO inhibition as a strategic approach to enhance immunogenic peptide presentation, thereby improving the efficacy of cancer immunotherapies.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Cell Suspension Culture

DISEASE(S): Lymphoma

SUBMITTER: Martin Klatt  

LAB HEAD: Martin Klatt

PROVIDER: PXD061196 | Pride | 2026-01-25

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
BC-1_HLA-I_D2.raw Raw
BC-1_HLA-I_D2.raw_20250213_Byonic.mgf Mgf
BC-1_HLA-I_D2.raw_20250213_Byonic.mzid Mzid
BC-1_HLA-I_E5.raw Raw
BC-1_HLA-I_E5.raw_20250213_Byonic.mgf Mgf
Items per page:
1 - 5 of 183

Similar Datasets

2024-05-29 | PXD045647 | Pride
2023-03-21 | PXD034772 | Pride
2021-09-10 | PXD024965 | Pride
2019-10-31 | E-MTAB-8483 | biostudies-arrayexpress
2024-05-29 | PXD019327 | Pride
2025-06-01 | PXD064480 | Pride
2016-05-31 | E-GEOD-82031 | biostudies-arrayexpress
2022-01-15 | PXD030506 | Pride
2008-05-31 | E-GEOD-9945 | biostudies-arrayexpress
2025-04-01 | E-MTAB-14654 | biostudies-arrayexpress